# Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients

> **NCT00577993** · PHASE3 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 210 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** Novantrone
- **DRUG:** Decadron
- **DRUG:** Rituximab
- **DRUG:** Interferon
- **DRUG:** Doxorubicin
- **DRUG:** Vincristine
- **DRUG:** Bleomycin
- **DRUG:** Cyclophosphamide
- **DRUG:** Etoposide
- **DRUG:** Cisplatin
- **DRUG:** Ara-C
- **DRUG:** Methyl-Prednisolone
- **DRUG:** Procarbazine
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT00577993
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-03-16
- **Primary completion:** 2017-08-24
- **Final completion:** 2017-08-24
- **Target enrollment:** 210 (ACTUAL)
- **Last updated:** 2020-11-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00577993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00577993, "Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00577993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*